Trial of ASCA101 for Cancer-Related Weight Loss
Part of Cancer clinical trials.
This trial tests a new drug, ASCA101, for people with certain cancers who are experiencing unwanted weight loss (cachexia). It aims to see if the drug can help improve appetite and stabilize weight. Participants must have colorectal, ovarian, or lung cancer and meet specific weight loss criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 or older with colorectal, ovarian, or lung cancer that has been confirmed by biopsy.
- You have had at least one of the following: unintentional weight loss >5% in 6 months, low BMI with >2% weight loss, or low muscle mass (sarcopenia) with >2% weight loss.
- You are able to eat by mouth and complete questionnaires.
- You are not taking any other appetite stimulants or weight gain medications.
- You do not have serious heart, kidney, or other medical conditions that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new drug called GB18 to help cancer patients who have experienced significant weight loss and muscle wasting—a condition called cancer cachexia. The drug works by targeting a specific protein involved in weight loss, and researchers want to learn if it can help patients regain weight and strength while also being safe.
This trial tests whether a postbiotic supplement can help people with advanced non-small-cell lung cancer who are losing weight (cachexia). If you're getting or have finished chemotherapy plus immunotherapy for stage III or IV NSCLC and have lost weight recently, you may be able to join.
This study tests a new medicine (QLS2319) to see if it’s safe and can help people with cancer-related weight loss and muscle loss (cachexia). It’s for people whose daily activities aren’t severely limited by their cancer.
This trial tests a new appetite-boosting medicine (nano-crystalline megestrol acetate) added to standard chemotherapy for people with advanced small cell lung cancer who are losing weight. It aims to see if it helps with weight, strength, and treatment response.
This study tests whether a drug called selpercatinib can help patients with advanced lung, pancreatic, or colorectal cancer who are losing weight while on chemotherapy. It aims to see if the drug is safe and might reverse or prevent further weight loss.
This study tests a new drug called GFS202A for people with advanced solid tumors who are experiencing weight loss or have a low body mass index (cachexia). The goal is to see if the drug is safe and can help improve appetite and weight.
Hear when a new Cachexia; Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.